ClinConnect ClinConnect Logo
Search / Trial NCT04132687

ABPT in Secondary Pneumothorax With Persistent Airleak Study

Launched by CHINESE UNIVERSITY OF HONG KONG · Oct 17, 2019

Trial Information

Current as of July 21, 2025

Unknown status

Keywords

Digital Chest Drain Device

ClinConnect Summary

The patient must have a chest tube in place and checked to be patent. Approximately 1.5ml/kg of venous blood will be withdrawn from the patient and immediately instilled it into the pleural cavity with aseptic technique via the chest tube already in situ. (There is no standard amount of blood used for ABPT. A small randomized study advocated that the use of 1.5ml/kg as it provided the optimal benefits.) The drain is then flushed with 20ml normal saline to avoid clotting. The tube of the drain is immediately elevated to 60cm above the insertion point of the chest tube at the patient's chest ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • aged 18 years or older;
  • radiographically proven pneumothorax and underlying lung disease (either pre-existing or shown in diagnostic imaging at presentation);
  • chest tube inserted which still shows an air leak at day 5 (or later) after the first radiographic evidence of a pneumothorax.
  • Exclusion Criteria:
  • inability to provide informed consent;
  • a chest tube smaller than 12 F (because of the risk of blockage by blood)
  • bilateral pneumothorax
  • uncorrectable coagulopathy
  • active or recent (within 6 weeks) pleural infection
  • use of long term steroid or immunosuppressant
  • septicaemia or active extrapleural infection (eg pneumonia)

About Chinese University Of Hong Kong

The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.

Locations

Hong Kong, , Hong Kong

Patients applied

0 patients applied

Trial Officials

Chun Li Dr Ngai

Principal Investigator

Chinese University of Hong Kong

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials